Cara Gets US Approval Of I.V. Korsuva, But Prospects Murky For Oral Version
The kappa opioid receptor agonist is not listed as a scheduled substance and labeling meets expectations. Cara and partner Vifor plan to launch the product in early 2022.
You may also be interested in...
The European Medicines Agency will likely decide this week whether to recommend for pan-EU approval new treatments for insomnia, uveal melanoma, migraine and advanced prostate cancer.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
An artificial intelligence and machine learning deal between BenevolentAI and AstraZeneca struck in 2019 has produced its first drug candidate.